A Phase 2 clinical trial of weekly oral ecnoglutide, also known as VRB-101, has been marked as completed as of August 17, 2026. The trial, registered as NCT07281937, is titled "A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities." It enrolled participants with obesity or overweight who also had weight-related comorbidities. The registration lists the study status as completed and identifies the trial phase as Phase 2. Ecnoglutide remains an unapproved compound currently in research and clinical development, not authorized for general use. This update reflects only the change in trial status recorded on ClinicalTrials.gov as of the listed date. No outcome data, efficacy findings, or safety results are included in this status update. Additional details about the trial design, participant criteria, or endpoints can be found in the official registration record. Readers seeking more background on this compound and its overall development history can consult the compound overview for further context.
Ecnoglutide (VRB-101) Phase 2 Obesity Trial Marked Completed
See the full ecnoglutide overview
Source: https://clinicaltrials.gov/study/NCT07281937